# ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

> **NCT01208090** · PHASE2 · COMPLETED · sponsor: **Actelion** · enrollment: 326 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** ACT-128800
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01208090
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-31
- **Primary completion:** 2012-10-31
- **Final completion:** 2012-11-30
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01208090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01208090, "ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT01208090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*